Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma

Stock Information for Telo Genomics Corp

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Telo Genomics Corp

Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
Small Cap Growth Virtual Investor Conference Agenda Announced for December 9th
Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th
Small Cap Growth Virtual Investor Conference Agenda Announced for December 9th
Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025
American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition
Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.